• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与尿激酶受体占据相关的细胞对玻连蛋白的可逆性黏附。

Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.

作者信息

Waltz D A, Chapman H A

机构信息

Department of Medicine, Harvard Medical School, Boston, Massachusetts.

出版信息

J Biol Chem. 1994 May 20;269(20):14746-50.

PMID:7514182
Abstract

Urokinase receptors are distributed on surfaces of many cell types where they are thought to focus plasminogen-dependent proteolysis important to migration and tissue remodeling to the immediate pericellular space. In addition to its well characterized role in proteolysis, urokinase receptor binding per se promotes the adhesiveness of leukemic cell lines exposed to differentiating cytokines in vitro. We sought to determine if a serum or matrix component is involved in urokinase-dependent adhesion. We now report that cytokine-stimulated human myelomonocytic cells express a divalent cation- and Arg-Gly-Asp-independent high affinity receptor for urea-purified vitronectin (Kd < 10 nM). Soluble native vitronectin does not effectively bind to the receptor, while cellular adhesion was noted to both urea-purified and native vitronectin when adsorbed to plastic. The activity of this receptor is tightly coupled to urokinase receptor occupancy. Urokinase receptor binding thus induces selective and reversible cellular adhesion to the matrix form of vitronectin. Because transfer of vitronectin-bound plasminogen activator inhibitor type 1 to urokinase promotes rapid turnover of receptor-bound enzyme, these results illuminate a novel binding cycle by which urokinase receptor occupancy coordinately regulates cellular adhesiveness and pericellular proteolysis.

摘要

尿激酶受体分布于多种细胞类型的表面,人们认为它们可将对迁移和组织重塑至关重要的纤溶酶原依赖性蛋白水解作用集中于紧邻细胞周围的空间。除了其在蛋白水解方面已得到充分表征的作用外,尿激酶受体本身的结合还能促进体外暴露于分化细胞因子的白血病细胞系的黏附性。我们试图确定血清或基质成分是否参与尿激酶依赖性黏附。我们现在报告,细胞因子刺激的人骨髓单核细胞表达一种对尿素纯化的玻连蛋白具有二价阳离子和精氨酸 - 甘氨酸 - 天冬氨酸非依赖性的高亲和力受体(解离常数<10 nM)。可溶性天然玻连蛋白不能有效地与该受体结合,而当吸附到塑料上时,尿素纯化的玻连蛋白和天然玻连蛋白均能引起细胞黏附。该受体的活性与尿激酶受体的占据紧密相关。因此,尿激酶受体的结合诱导细胞对玻连蛋白基质形式进行选择性和可逆性黏附。由于结合在玻连蛋白上的1型纤溶酶原激活物抑制剂向尿激酶的转移促进了受体结合酶的快速周转,这些结果揭示了一个新的结合循环,通过该循环尿激酶受体的占据协同调节细胞黏附性和细胞周围蛋白水解作用。

相似文献

1
Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.与尿激酶受体占据相关的细胞对玻连蛋白的可逆性黏附。
J Biol Chem. 1994 May 20;269(20):14746-50.
2
Identification of the urokinase receptor as an adhesion receptor for vitronectin.鉴定尿激酶受体为玻连蛋白的粘附受体。
J Biol Chem. 1994 Dec 23;269(51):32380-8.
3
Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.细胞因子诱导人髓样细胞的尿激酶依赖性黏附。纤溶酶原激活物抑制剂的调节作用。
J Clin Invest. 1993 Apr;91(4):1541-52. doi: 10.1172/JCI116360.
4
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.在尿激酶受体表达时,玻连蛋白和尿激酶在调节细胞形态方面的复合作用。
J Biol Chem. 2008 May 30;283(22):15217-23. doi: 10.1074/jbc.C700214200. Epub 2008 Mar 24.
5
Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.尿激酶型纤溶酶原激活剂(u-PA)与玻连蛋白的特异性结合及其在介导U937细胞的u-PA依赖性黏附中的作用。
Biochem J. 1995 May 1;307 ( Pt 3)(Pt 3):867-73. doi: 10.1042/bj3070867.
6
Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87).百日咳毒素诱导骨髓单核细胞黏附的机制:Mac-1(CD11b/CD18)和尿激酶受体(CD87)的作用
Immunology. 1996 May;88(1):90-7. doi: 10.1046/j.1365-2567.1996.d01-646.x.
7
Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.巨噬细胞-1(CD11b/CD18)与尿激酶受体(CD87)在单核细胞上形成一个功能单元。
Blood. 1996 Oct 15;88(8):3185-94.
8
Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.纤溶酶和1型纤溶酶原激活物抑制剂通过调节尿激酶受体与玻连蛋白之间的相互作用来促进细胞运动。
J Clin Invest. 1997 Jul 1;100(1):58-67. doi: 10.1172/JCI119521.
9
Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.玻连蛋白受体与尿激酶型纤溶酶原激活物受体在转移性黑色素瘤细胞中的协同表达。
J Clin Invest. 1995 May;95(5):2096-103. doi: 10.1172/JCI117897.
10
Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins.涉及尿激酶受体和β2整合素的锌依赖性白细胞黏附的分子机制。
Blood. 1999 May 1;93(9):2976-83.

引用本文的文献

1
suPAR to Risk-Stratify Patients With Malaria.可溶性尿激酶型纤溶酶原激活物受体(suPAR)用于疟疾患者的风险分层。
Front Immunol. 2022 Jun 10;13:931321. doi: 10.3389/fimmu.2022.931321. eCollection 2022.
2
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.癌症中针对尿激酶及其受体的治疗策略
Cancers (Basel). 2022 Jan 19;14(3):498. doi: 10.3390/cancers14030498.
3
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
4
Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.以非侵入性成像和治疗干预为目的,针对人类疾病中的尿激酶型纤溶酶原激活物受体(uPAR)
Front Cell Dev Biol. 2021 Aug 20;9:732015. doi: 10.3389/fcell.2021.732015. eCollection 2021.
5
The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis.纤溶酶原激活系统在血管性水肿中的作用:发病机制的新见解
J Clin Med. 2021 Feb 1;10(3):518. doi: 10.3390/jcm10030518.
6
MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.MUC1蛋白通过与NF-κB p65转录因子形成复合物并结合uPA启动子来诱导尿激酶型纤溶酶原激活剂(uPA),从而导致癌细胞侵袭性增强。
J Biol Chem. 2014 Dec 19;289(51):35193-204. doi: 10.1074/jbc.M114.586461. Epub 2014 Nov 4.
7
Role of urokinase receptor in tumor progression and development.尿激酶受体在肿瘤演进和发展中的作用。
Theranostics. 2013 Jun 25;3(7):487-95. doi: 10.7150/thno.4218. Print 2013.
8
Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.基于结构的放射性核素示踪剂设计用于 uPAR 的非侵入性成像和靶向放射治疗。一个合成肽拮抗剂的故事。
Theranostics. 2013 Jun 24;3(7):467-76. doi: 10.7150/thno.3791. Print 2013.
9
VEGF-initiated angiogenesis and the uPA/uPAR system.VEGF 引发的血管生成和 uPA/uPAR 系统。
Cell Adh Migr. 2012 Nov-Dec;6(6):535-615. doi: 10.4161/cam.22243. Epub 2012 Oct 17.
10
A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).一个灵活的多结构域结构驱动尿激酶型纤溶酶原激活物受体(uPAR)的功能。
J Biol Chem. 2012 Oct 5;287(41):34304-15. doi: 10.1074/jbc.M112.398404. Epub 2012 Aug 15.